Jim Knight joined BioTime as the Senior Vice President, Head of Corporate Development in October, 2016. Jim brings over 20 years of biotech and pharmaceutical experience to BioTime. He was previously the Vice President of Portfolio Strategy at Questcor from 2010 through 2014, helping drive portfolio expansion from less than $150 million to over $1 billion by strategically expanding promoted opportunities. Questcor was acquired by Mallinckrodt Pharmaceuticals for $5.6 billion in 2014 and Jim stayed on for a transition and integration period through 2015. Prior to Questcor, Jim was at Elan Pharmaceuticals from 2001 to 2008 where he led a global strategic marketing team, working closely with collaborators at Biogen Inc. on the successful development and commercialization of Tysabri. Prior to Elan, Jim worked in a variety of marketing and analytical roles at the specialty pharmaceutical company Dura Pharmaceuticals from 1998 to 2000. Jim started his career at Biogen, in the research group and then moved on to sales and market analysis roles from 1993 to 1998. Jim has a BS in Biology from the University of Massachusetts and an MBA in High Technology from Northeastern University.

 Biology